Article Text

Download PDFPDF
Original research
Dynamics of cerebral perfusion and oxygenation parameters following endovascular treatment of acute ischemic stroke
  1. Gianluca Brugnara1,
  2. Christian Herweh1,
  3. Ulf Neuberger1,
  4. Mikkel Bo Hansen2,
  5. Christian Ulfert1,
  6. Mustafa Ahmed Mahmutoglu1,
  7. Martha Foltyn1,
  8. Simon Nagel3,
  9. Silvia Schönenberger3,
  10. Sabine Heiland1,
  11. Peter Arthur Ringleb3,
  12. Martin Bendszus1,
  13. Markus Möhlenbruch1,
  14. Johannes Alex Rolf Pfaff1,
  15. Philipp Vollmuth1
  1. 1Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Baden-Württemberg, Germany
  2. 2Center of Functionally Integrative Neuroscience and MINDLab, Aarhus Universitet, Aarhus, Midtjylland, Denmark
  3. 3Department of Neurology, Heidelberg University Hospital, Heidelberg, Baden-Württemberg, Germany
  1. Correspondence to Dr Philipp Vollmuth, Department of Neuroradiology, University Hospital Heidelberg, Heidelberg 69120, Baden-Württemberg, Germany; philipp.vollmuth{at}med.uni-heidelberg.de

Abstract

Background We studied the effects of endovascular treatment (EVT) and the impact of the extent of recanalization on cerebral perfusion and oxygenation parameters in patients with acute ischemic stroke (AIS) and large vessel occlusion (LVO).

Methods Forty-seven patients with anterior LVO underwent computed tomography perfusion (CTP) before and immediately after EVT. The entire ischemic region (Tmax >6 s) was segmented before intervention, and tissue perfusion (time-to-maximum (Tmax), time-to-peak (TTP), mean transit time (MTT), cerebral blood volume (CBV), cerebral blood flow (CBF)) and oxygenation (coefficientof variation (COV), capillary transit time heterogeneity (CTH), metabolic rate of oxygen (CMRO2), oxygen extraction fraction (OEF)) parameters were quantified from the segmented area at baseline and the corresponding area immediately after intervention, as well as within the ischemic core and penumbra. The impact of the extent of recanalization (modified Treatment in Cerebral Infarction (mTICI)) on CTP parameters was assessed with the Wilcoxon test and Pearson’s correlation coefficients.

Results The Tmax, MTT, OEF and CTH values immediately after EVT were lower in patients with complete (as compared with incomplete) recanalization, whereas CBF and COV values were higher (P<0.05) and no differences were found in other parameters. The ischemic penumbra immediately after EVT was lower in patients with complete recanalization as compared with those with incomplete recanalization (P=0.002), whereas no difference was found for the ischemic core (P=0.12). Specifically, higher mTICI scores were associated with a greater reduction of ischemic penumbra volumes (R²=−0.48 (95% CI –0.67 to –0.22), P=0.001) but not of ischemic core volumes (P=0.098).

Conclusions Our study demonstrates that the ischemic penumbra is the key target of successful EVT in patients with AIS and largely determines its efficacy on a tissue level. Furthermore, we confirm the validity of the mTICI score as a surrogate parameter of interventional success on a tissue perfusion level.

  • angiography
  • CT perfusion
  • stroke
  • thrombectomy
  • intervention

Statistics from Altmetric.com

Footnotes

  • Twitter @GianBrugna, @vollmuthp

  • Contributors Research concept and design: PV, GB, MB. Data acquisition: all authors. Imaging data post-processing: GB, MAM, MF, UN. Data analysis and interpretation: GB, PV. Statistical analysis: GB, PV. Drafting the manuscript: PV, GB. Critical revision of the manuscript for important intellectual content: all authors. Responsibility for funding and supervision: PV.

  • Funding PV was supported by the Else Kroner-Fresenius Foundation (Else-Kroner Memorial Scholarship).

  • Competing interests Additionally, the authors disclose the following relationships with companies unrelated to this research project. SN: consultancy: Brainomix, Boehringer Ingelheim; payment for lectures including service on speakers' bureaus: Pfizer, Medtronic, Bayer AG. CH: consultancy: Brainomix, Oxford, UK; comments: <€10,000. CU: travel/accommodation/meeting expenses unrelated to activities listed: MicroVention, Stryker. SH: grants/grants pending: Deutsche Forschungsgemeinschaft (DFG) - SFB 1118. MB: board membership: Data and Safety Monitoring Board for Vascular Dynamics, Guerbet, Boehringer Ingelheim; consultancy: Codman, Roche Diagnostics, Guerbet, Boehringer Ingelheim, BBRaun, Merck; grants/grants pending: DFG, Hopp Foundation, Novartis, Siemens, Guerbet, Stryker, Covidien, EU; payment for lectures including service on speakers' bureaus: Novartis, Roche Diagnostics, Guerbet, Teva Pharmaceutical Industries, Bayer AG, Codman. MM: board membership: Codman; consultancy: Medtronic, MicroVention, Stryker; payment for lectures including service on speakers' bureaus: Medtronic, MicroVention, Stryker; grants/grants pending: Balt. *Money paid to the institution. JARP: payment for lectures including service on speakers' bureaus: Siemens; travel/accommodation/meeting expenses unrelated to activities listed: Stryker, MicroVention. PAR: consultancy: Bayer, Pfizer, Daiichi Sankyo; personal fees: Boehringer Ingelheim.

  • Patient consent for publication Not required.

  • Ethics approval University of Heidelberg No. S-303/2014 and S-784/2018.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request by contacting the corresponding author.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.